Head-to-head evidence
CL-197 vs Rilpivirine
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV reverse transcriptase · full HIV pipeline
CL-197
Developed by Henan Genuine Biotech
NCT05944848 · Phase 1 · completed
The study randomly assigned healthy volunteers to active drug or matching placebo and blinded participants, care providers, investigators, and outcome assessors, which are the hallmarks of a well-controlled study. However, it tested only safety and drug levels in healthy volunteers rather than any HIV outcome, and results have not been posted.
Next expected readout: December 2026 · NCT07308782 (registry estimate)
Rilpivirine · Edurant
Marketed by Johnson & Johnson and partners
NCT00540449 · Phase 3 · completed
This was a large (690-participant), randomized, quadruple-blinded, active-controlled (efavirenz) phase 3 trial with a hard clinical endpoint (confirmed viral load <50 copies/mL). The pre-specified non-inferiority margin was clearly met, with the confidence interval for the treatment difference falling entirely within the allowed -12% boundary, so rilpivirine was shown to be as effective as efavirenz on the primary measure despite a somewhat higher rate of virologic failure and resistance emergence as a secondary finding.
Next expected readout: October 2026 · NCT05660980 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: CL-197's landscape · Rilpivirine's landscape